Clinical Characteristics
| Median age (range) | 32 (17-49) |
| Underlying disease and status | |
| Acute leukemia | 31 |
| First complete remission | 18 |
| Second complete remission | 6 |
| Refractory disease | 4 |
| Early untreated relapse | 3 |
| Chronic myeloid leukemia | 19 |
| First chronic phase | 14 |
| Advanced disease | 5 |
| Severe aplastic anemia | 4 |
| Myelodysplastic syndrome | 4 |
| Multiple myeloma | 1 |
| Donors | |
| HLA identical sibling | 56 |
| Unrelated (A, B, DRB1 identical) | 2 |
| One mismatched family donor | 1 |
| Second BMT | 3 |
| Conditioning regimen | |
| BuCy2 | 37 |
| CyTBI | 15 |
| CyTLI | 3 |
| BuCyVP16 | 2 |
| Cy-ATG | 1 |
| CyTBI Thiotepa | 1 |
| VOD | 9/59 (15%) |
| Fatal VOD | 2/59 (3,3%) |
| Acute grade II-IV GVHD | 21/56 (37,5%) |
| Chronic GVHD | 14/43 (32,5%) |
| Status: alive/dead | 40/19 |
| Causes of death | |
| Acute GVHD infection | 7 |
| Relapse | 7 |
| VOD | 2 |
| CMV interstitial pneumonitis | 1 |
| Multiorgan failure and sepsis | 1 |
| Hemorrhage | 1 |
| Median age (range) | 32 (17-49) |
| Underlying disease and status | |
| Acute leukemia | 31 |
| First complete remission | 18 |
| Second complete remission | 6 |
| Refractory disease | 4 |
| Early untreated relapse | 3 |
| Chronic myeloid leukemia | 19 |
| First chronic phase | 14 |
| Advanced disease | 5 |
| Severe aplastic anemia | 4 |
| Myelodysplastic syndrome | 4 |
| Multiple myeloma | 1 |
| Donors | |
| HLA identical sibling | 56 |
| Unrelated (A, B, DRB1 identical) | 2 |
| One mismatched family donor | 1 |
| Second BMT | 3 |
| Conditioning regimen | |
| BuCy2 | 37 |
| CyTBI | 15 |
| CyTLI | 3 |
| BuCyVP16 | 2 |
| Cy-ATG | 1 |
| CyTBI Thiotepa | 1 |
| VOD | 9/59 (15%) |
| Fatal VOD | 2/59 (3,3%) |
| Acute grade II-IV GVHD | 21/56 (37,5%) |
| Chronic GVHD | 14/43 (32,5%) |
| Status: alive/dead | 40/19 |
| Causes of death | |
| Acute GVHD infection | 7 |
| Relapse | 7 |
| VOD | 2 |
| CMV interstitial pneumonitis | 1 |
| Multiorgan failure and sepsis | 1 |
| Hemorrhage | 1 |
Abbreviations: Bu, busulfan; Cy, cyclophosphamide; TLI, total lymphoid irradiation; VOD, venoocclusive disease of the liver; GVHD, graft-versus-host disease; CMV, cytomegalovirus.